Cowen and Company’s Nektar Therapeutics NKTR Stock Holding History

Cowen and Company’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,566	Closed	-$487K	–	605
2020 Q4	$399K	Buy	+1,566	New	+$405K	0.04%	127

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Cowen and Company's NKTR Position: Q1 2021 in Review

Cowen and Company sold out of Nektar Therapeutics (NKTR) in Q1 2021, closing a stake of 1,566 shares — an estimated $487K sold.

Cowen and Company first reported a position in NKTR in Q4 2020 and held it in 1 quarter. The position peaked at $399K in Q4 2020. 236 funds tracked by Wall St. Rank hold NKTR as of Q1 2021.

Cowen and Company reported no remaining Nektar Therapeutics position as of Q1 2021 after selling out during the quarter.
Cowen and Company sold 1,566 Nektar Therapeutics shares in Q1 2021, an estimated $487K.
Cowen and Company first reported a position in Nektar Therapeutics in Q4 2020 and held it in 1 quarter.
Cowen and Company's Nektar Therapeutics position peaked at $399K in Q4 2020.
236 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2021.

Based on Cowen and Company's 13F filing for Q1 2021, filed 4 May 2021.